Myeloid transformation of plasma cell myeloma: molecular evidence of clonal evolution revealed by next generation sequencing.
Gralewski JH et al. Diagn Pathol. 2018 Feb 20;13(1):15. doi: 10.1186/s13000-018-0692-1.
The transmembrane protein TMEPAI induces myeloma cell apoptosis by promoting degradation of the c-Maf transcription factor.
Du Y et al. J Biol Chem. 2018 Feb 21. pii: jbc.RA117.000972. doi: 10.1074/jbc.RA117.000972. [Epub ahead of print].
Loss of heterozygosity as a marker of homologous repair deficiency in multiple myeloma: a role for PARP inhibition?
Pawlyn C et al. Leukemia. 2018 Feb 2. doi: 10.1038/s41375-018-0017-0. [Epub ahead of print].
Targeting MYC in multiple myeloma.
Jovanović KK et al. Leukemia. 2018 Feb 22. doi: 10.1038/s41375-018-0036-x. [Epub ahead of print].
1,2,3,4,6-Penta-O-Galloyl-Beta-D-Glucopyranoside Inhibits Proliferation of Multiple Myeloma Cells Accompanied with Suppression of MYC Expression.
Tseeleesuren D et al.Front Pharmacol. 2018 Feb 2;9:65. doi: 10.3389/fphar.2018.00065. eCollection 2018.
Deficient invariant natural killer T cells had impaired regulation on osteoclastogenesis in myeloma bone disease.
Jiang F et al. J Cell Mol Med. 2018 Feb 23. doi: 10.1111/jcmm.13554. [Epub ahead of print].
Characterization of CD4+ T cell-mediated cytotoxicity in patients with multiple myeloma.
Zhang X et al. Cell Immunol. 2018 Feb 12. pii: S0008-8749(18)30058-3. doi: 10.1016/j.cellimm.2018.02.009. [Epub ahead of print].
Focusing on long non-coding RNA dysregulation in newly diagnosed multiple myeloma.
Shen Y et al. Life Sci. 2018 Mar 1;196:133-142. doi: 10.1016/j.lfs.2018.01.025. Epub 2018 Feb 3.
PI3K/Akt inhibitor LY294002 potentiates homoharringtonine antimyeloma activity in myeloma cells adhered to stromal cells and in SCID mouse xenograft.
Chen P et al. Ann Hematol. 2018 Feb 15. doi: 10.1007/s00277-018-3247-3. [Epub ahead of print].
Identification of novel fusion transcripts in multiple myeloma.
Lin M et al. J Clin Pathol. 2018 Feb 16. pii: jclinpath-2017-204961. doi: 10.1136/jclinpath-2017-204961. [Epub ahead of print].
Proteomic characterization of Withaferin A-targeted protein networks for the treatment of monoclonal myeloma gammopathies.
Dom M et al. J Proteomics. 2018 Feb 12. pii: S1874-3919(18)30061-7. doi: 10.1016/j.jprot.2018.02.013. [Epub ahead of print].
Pirh2 mediates the sensitivity of myeloma cells to bortezomib via canonical NF-κB signaling pathway.
Yang L et al. Protein Cell. 2018 Feb 13. doi: 10.1007/s13238-017-0500-9. [Epub ahead of print].
The small GTPase RhoU lays downstream of JAK/STAT signaling and mediates cell migration in multiple myeloma.
Canovas Nunes S et al. Blood Cancer J. 2018 Feb 13;8(2):20. doi: 10.1038/s41408-018-0053-z.
Targeting HSF1: a prime integrator of proteotoxic stress response in myeloma.
Parekh S. Clin Cancer Res. 2018 Feb 9. pii: clincanres.0030.2018. doi: 10.1158/1078-0432.CCR-18-0030. [Epub ahead of print].
Platelets enhance Multiple Myeloma progression via IL-1β upregulation.
Takagi S et al. Clin Cancer Res. 2018 Feb 9. pii: clincanres.2003.2017. doi: 10.1158/1078-0432.CCR-17-2003. [Epub ahead of print].
Activin A induces apoptosis of mouse myeloma cells via the mitochondrial pathway.
Zhang Y et al. Oncol Lett. 2018 Feb;15(2):2590-2594. doi: 10.3892/ol.2017.7584. Epub 2017 Dec 11.
Dihydroartemisinin treatment of multiple myeloma cells causes activation of c-Jun leading to cell apoptosis.
Wang Y et al. Oncol Lett. 2018 Feb;15(2):2562-2566. doi: 10.3892/ol.2017.7582. Epub 2017 Dec 11.
Dual inhibition of mTORC1/2 by DCZ0358 induces cytotoxicity in multiple myeloma and overcomes the protective effect of the bone marrow microenvironment.
Gao L et al. Cancer Lett. 2018 Feb 8. pii: S0304-3835(18)30136-8. doi: 10.1016/j.canlet.2018.02.009. [Epub ahead of print].
Emerging immune targets for the treatment of multiple myeloma.
Sohail A et al. Immunotherapy. 2018 Feb 1;10(4):265-282. doi: 10.2217/imt-2017-0136.
Cytogenetic aberrations in multiple myeloma are associated with shifts in serum immunoglobulin isotypes distribution and levels.
Yadav P et al. Haematologica. 2018 Feb 1. pii: haematol.2017.184226. doi: 10.3324/haematol.2017.184226. [Epub ahead of print].
Impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed/refractory multiple myeloma.
van de Donk NWCJ et al. Br J Haematol. 2018 Feb 7. doi: 10.1111/bjh.15122. [Epub ahead of print].
Pleomorphic multinucleated plasma cells simulating megakaryocytes in anaplastic variant of myeloma.
Harankhedkar S et al. Turk J Haematol. 2018 Feb 6. doi: 10.4274/tjh.2017.0329. [Epub ahead of print].
Tumor suppressor CD99 is downregulated in plasma cell neoplasms lacking CCND1 translocation and distinguishes neoplastic from normal plasma cells and B-cell lymphomas with plasmacytic differentiation from primary plasma cell neoplasms.
Gao Q et al. Mod Pathol. 2018 Feb 5. doi: 10.1038/s41379-018-0011-0. [Epub ahead of print].
Comparative Analysis of miRNA Expression Profiles of Multiple Myelomawith 1q21 Gains and Normal FISH.
Cui Y et al. Acta Haematol. 2018 Feb 2;139(2):96-100. doi: 10.1159/000486662. [Epub ahead of print].
HSF1 Is Essential for Myeloma Cell Survival and A Promising Therapeutic Target.
Fok JHL et al. Clin Cancer Res. 2018 Feb 1. doi: 10.1158/1078-0432.CCR-17-1594. [Epub ahead of print].
Novel pedigree analysis implicates DNA repair and chromatin remodeling in multiple myeloma risk.
Waller RG et al. PLoS Genet. 2018 Feb 1;14(2):e1007111. doi: 10.1371/journal.pgen.1007111. eCollection 2018 Feb.
Long Non-Coding RNAs in Multiple Myeloma.
Nobili L et al. Genes (Basel). 2018 Feb 1;9(2). pii: E69. doi: 10.3390/genes9020069.
Heterochronous occurrence of microsatellite instability in multiple myeloma- an implication for a role of defective DNA mismatch repair in myelomagenesis.
Miyashita K et al. Leuk Lymphoma. 2018 Jan 31:1-6. doi: 10.1080/10428194.2018.1427862. [Epub ahead of print].